BACKGROUND: Performance characteristics of novel rapid drug susceptibility tests (DST) for Mycobacterium tuberculosis may change when moving from research to implementation in actual public health practice. We describe the performance characteristics of a direct, rapid DST when implemented in Lima, Peru. METHODS: A district laboratory validated conventional proportions and nitrate reductase methods. We collected data on samples submitted for DST from January 2005 to June 2007 and calculated frequency of testing and results, and median time to test results. RESULTS: A total of 4102 DSTs were performed by conventional DST and 895 by nitrate reductase. Results were obtained from 72.8% of samples by conventional DST and from 70.2% of those processed by Griess; respectively 26.4% and 31.5% were multidrug-resistant tuberculosis. The median time from sample collection to test result was 31 days for Griess vs. 99 days for conventional DST. CONCLUSIONS: Preliminary experience with the Griess method demonstrates favorable performance under program conditions.
BACKGROUND: Performance characteristics of novel rapid drug susceptibility tests (DST) for Mycobacterium tuberculosis may change when moving from research to implementation in actual public health practice. We describe the performance characteristics of a direct, rapid DST when implemented in Lima, Peru. METHODS: A district laboratory validated conventional proportions and nitrate reductase methods. We collected data on samples submitted for DST from January 2005 to June 2007 and calculated frequency of testing and results, and median time to test results. RESULTS: A total of 4102 DSTs were performed by conventional DST and 895 by nitrate reductase. Results were obtained from 72.8% of samples by conventional DST and from 70.2% of those processed by Griess; respectively 26.4% and 31.5% were multidrug-resistant tuberculosis. The median time from sample collection to test result was 31 days for Griess vs. 99 days for conventional DST. CONCLUSIONS: Preliminary experience with the Griess method demonstrates favorable performance under program conditions.
Authors: Carol Dukes Hamilton; Timothy R Sterling; Henry M Blumberg; Michael Leonard; James McAuley; David Schlossberg; Jason Stout; Gwen Huitt Journal: Clin Infect Dis Date: 2007-06-22 Impact factor: 9.079
Authors: H Lin; S Shin; J A Blaya; Z Zhang; P Cegielski; C Contreras; L Asencios; C Bonilla; J Bayona; C J Paciorek; T Cohen Journal: Epidemiol Infect Date: 2010-12-23 Impact factor: 2.451
Authors: S S Shin; L Asencios; M Yagui; G Yale; C Suárez; J Bayona; C Bonilla; O Jave; C C Contreras; S Atwood; J A Blaya; J Ershova; J P Cegielski Journal: Int J Tuberc Lung Dis Date: 2012-09-14 Impact factor: 2.373
Authors: Gustavo E Velásquez; Martin Yagui; J Peter Cegielski; Luis Asencios; Jaime Bayona; Cesar Bonilla; Hector O Jave; Gloria Yale; Carmen Suárez; Sidney Atwood; Carmen C Contreras; Sonya S Shin Journal: Emerg Infect Dis Date: 2011-03 Impact factor: 6.883
Authors: J Coronel; M H Roper; C Herrera; C Bonilla; O Jave; C Gianella; I Sabogal; V Huancaré; E Leo; A Tyas; A Mendoza-Ticona; L Caviedes; D A J Moore Journal: Clin Microbiol Infect Date: 2013-11-21 Impact factor: 8.067
Authors: Gustavo E Velásquez; J Peter Cegielski; Megan B Murray; Martin J A Yagui; Luis L Asencios; Jaime N Bayona; César A Bonilla; Hector O Jave; Gloria Yale; Carmen Z Suárez; Eduardo Sanchez; Christian Rojas; Sidney S Atwood; Carmen C Contreras; Janeth Santa Cruz; Sonya S Shin Journal: BMC Infect Dis Date: 2016-02-01 Impact factor: 3.090